Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$202.18 USD

202.18
2,303,503

+0.50 (0.25%)

Updated Nov 6, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $117.63, moving +0.9% from the previous trading session.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal

Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $115.17 in the latest trading session, marking a +0.8% move from the prior day.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ABBV vs. NVO: Which Stock Is the Better Value Option?

ABBV vs. NVO: Which Stock Is the Better Value Option?

Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year?

Is (ABBV) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates

EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.

Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck

Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $113 in the latest trading session, marking a +0.02% move from the prior day.

AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA

The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.

Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study

Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $114.73 in the latest trading session, marking a +1.42% move from the prior day.

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $115.40, marking a -0.02% move from the previous day.

Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended

Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.

argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $113.01 in the latest trading session, marking a +0.58% move from the prior day.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved

The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up

Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.